Giordano Christopher Thomas 4

4 · TENAX THERAPEUTICS, INC. · Filed May 20, 2025

Form 4

Period: 2025-05-16

DirectorCEO

Transactions

Award
Stock Option (right to buy)
2025-05-16+1,400,000→ 1,400,000 total
Exercise: $5.89Exp: 2035-05-16→ Common Stock (1,400,000 underlying)

Holdings

Stock Option (right to buy)
Exercise: $992.00Exp: 2032-06-09→ Common Stock (125 underlying)
125
Stock Option (right to buy)
Exercise: $3.55Exp: 2034-05-17→ Common Stock (437 underlying)
437
Stock Option (right to buy)
Exercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (1,250,000 underlying)
1,250,000
Stock Option (right to buy)
Exercise: $3152.00Exp: 2031-07-06→ Common Stock (157 underlying)
157

Footnotes (4)

[F1]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
[F2]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
[F3]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
[F4]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.

Documents

1 file